State ID: _		Date	of Initial Cult	ture (<i>mm/dd/</i>	<i>(yyyy</i>):/	'/	Surv	eillance (Office Initials	s
Patient name	:		CANDIDEN	1IA 2017 CA	SE REPOR'					
ducific flame	(Last,	First, MI)			cai recora ive	J				
Address:	ımber, Street, Apt. No.)			·	oital:					
					•	,				
	ry, State)		(Zip Code)		Acc No. (subseq isolate): portion above at EIP site					
Check if not		Ευι,	rtear Here and	тегант рогион а	above at EIP !	SILE				
	a case: □Out of c	atchment area	Duplicate enti	y □Not candi	demia 🔲 Una	able to verify	address	Other (spe	ecify):	
	NCE OFFICER IN									
1. Date repo	orted to EIP site:	3. Was case f	first	5. Previous ca	andidemia e	pisode?			6. CRF stat	tus: 7. SO's initials:
				1 □Yes 0 □N 5a. If yes, ente		own 			1 □Comple	ete
2. Date revi	ew completed:			Ja. II yes, ente	i state ibs.				2 Pending	g
		4. Isolate ava							4 □Chart unavailable	
			iU						uriavaliable	
DEMOGRAF	PHICS									
8. State ID:		<u> </u>	9. State:		10.	County: _				
11. Lab ID v	where positive cul	ture was identif	ied:							
12. Date of	birth (mm/dd/yyyy)	: 1	3. Age:			14.	Sex:			
			1	□days 2 □m	os 3 🗌 yrs		emale Ma		heck if transge	ender
15. Race (ch ☐White	heck all that apply	_	Mativo Hawai	ian/Pacific Islan	dor		Ethnic origi Hispanic/Lat			
□ Black/Afric	an American			ian/Alaska Nativ			Not Hispanic			
Asian	arr / arrettearr]Unknown	iany naoka matri	,		Unknown	, Latino		
LABORATO	RY DATA		30			, 0	0			
17. Date ini	tial positive <i>Candi</i>	ida blood culture	was drawn	(mm/dd/yyyy):						
	of initial positive (Candida blood cu	ılture 19.	. <i>Candida</i> spec	cies from ini	tial positiv	e blood cul	ture (che	ck all that ap	pply):
(check all th 1 □Blood, from			1 [Candida albica	ans (CA)	6 Г]Candida tro	nicalic (CT	1	
	om peripheral stick			□ Candida aibica □ Candida glabra	. ,				pecify:	
3 □Blood, no				□ Candida kruse	. ,				egative/non al	
4 □Other (sp	•			☐ Candida lusita.	• •] <i>Candida</i> spe			.5.00.15 (55.1)
9 Unknowr					` ,		Pending	(,		
20. Antifund	gal susceptibility t	esting (check he	ere 🗆 if no to	esting done/n	o test repor	ts availabl	e):			
-	Date of culture	Species		rug	MIC		-	retation		
		1 □CA	Ampho	otericin B		□s	□SDD []I 🔲	R □NS	
		2 □CG	Anidulafu	ngin (Eraxis)		□s	□SDD []I 🗆	R □NS	
		3 □CK		in (Cancidas)		□s		I 🗆		
		4 □CL 5 □CP		le (Diflucan)		□s]I 🗆		
		6 □CT		sine (5FC)		□S]I		
		7		le (Sporanox)		□S				
		8 □CGN		zole (Noxafil)		□S				
		9		zole (Vfend)		□s		JI 🗆		
		10 Pending		` ,						
		1 □CA 2 □CG		otericin B ngin (Eraxis)		□S				
		2 □CG 3 □CK		in (Cancidas)		□S				
		4 □CL		le (Diflucan)		□S		Ji 🗆		
		5 □CP		sine (5FC)		□s		JI 🗆		
		6 □CT	Itraconazo	le (Sporanox)		□s]I 🔲		
		7 □CO 8 □CGN	Micafungir	n (Mycamine)		□s	□SDD []I 🗆	R □NS	
		8 ∐CGN 9 □CS	Posaconaz	zole (Noxafil)		□s	□SDD []I 🗆	R □NS	
		10 □Pending	Voricona	zole (Vfend)		□s	□SDD [∃I □	R □NS	Page 1 of 5

State ID:	Date of Initial Culture (mm/dd/yyyy):/_	_/ Surveillance Office Initials
21. Additional non-Candida organisms	isolated from blood cultures on the same day as	s initial culture date: 1 \(\text{Yes} \) 0 \(\text{No} \) 9 \(\text{Unknown} \)
21a. If yes, additional organisms (Enter up t	o 3 pathogens):,,	
22. Any subsequent positive <i>Candida</i> bl	ood cultures in the 30 days after initial culture	date? 1 ☐Yes 0 ☐No 9 ☐Unknown
22a. If yes, provide dates of all subsequent pate Drawn (mm/dd/yyyy)	positive <i>Candida</i> blood cultures and select the species Species identified*	:
	□CA □CG □CK □CL □CP □CT	□CO: □CGN □CS □Pending
	□CA □CG □CK □CL □CP □CT	□CO: □CGN □CS □Pending
		□CO: □CGN □CS □Pending
		_
*Attach additional MIC page if additional		□CO: □CGN □CS □Pending er <i>C. glabrata</i> (even if original was <i>C. glabrata</i>), or if
same Candida species (if no AFST results a	available for original)	
23. Documented negative <i>Candida</i> bloo	d culture in the 30 days after initial culture dat	e? 1 □Yes 0 □No 9 □Unknown
23a. If yes, date of first negative Candida blo	ood culture://	
24. Other known sites of <i>Candida</i> infect 1 ☐ Yes 0 ☐ No 9 ☐ Unknown	tion or colonization in the 7 days before or 3 da	ys after initial culture date?
24a. If yes, source (check all that apply):		
1 ☐Peritoneal fluid or abdominal cavity	4 ☐Pleural fluid	7 □Skin
2 Urine	5 □CSF	8 ☐Other site (specify):
3 ☐Respiratory specimen	6 □Bone	
MEDICAL ENCOUNTERS		
25. Is patient currently hospitalized or	was patient hospitalized in the 7 days after init	ial culture date? 1 Yes 0 No 9 Unknown
25a. If yes, Treatment hospital ID	Date of admission vn	Date of discharge n ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐
26. Where was the patient located pri	•	
1 Private residence	3 LTCF Facility ID:	6 ☐Incarcerated
2 Hospital Inpatient (If transferred from	4 ☐LTACH Facility ID:	7 Other (specify):
another hospital, facility ID:	5 Homeless	9 ☐Unknown
	□Died 9 □Unknown	
27a. If survived, Date of last patient enco	Dunter 27b. If died, Date of Unknown	death / Unknown
28. If survived, discharged to:	hospitalized) 2 Dl ong term asute	care beenital Facility ID:
0 ☐ Not applicable (i.e., patient died, or not		care hospital Facility ID:
1 Private residence		
4 ☐ Another acute care hospital Facility ID:	9	
2 Long term care facility Facility ID:	<u>italization</u> in the 90 days <u>before</u> , initial culture o	date? 1 Yes 0 No 9 Unknown
UNDERLYING CONDITIONS	mene so days <u>serore</u> , miliar cartare	adec. 1 [163 0 [110] [onklown
30. Underlying conditions (Check all th	nat apply): None Unknown	
□Alcohol abuse, current	Congestive Heart Failure	☐Neurological Condition
☐ Chronic Cognitive Deficit/Dementia	☐Connective Tissue Disease	☐ Obesity or Morbid Obesity
Chronic Kidney Disease	CVA/Stroke/TIA	Pepcid Ulcer Disease
☐Creatinine ≥3	Cystic Fibrosis	Peripheral Vascular Disease (PVD)
Chronic Liver Disease	Diabetes Mellitus	☐Plegias/Paralysis
☐Cirrhosis ☐Ascites	☐With Chronic Complications ☐HIV	☐ Hemiplegia
☐ Hepatic Encephalopathy	☐AIDS/CD4 count <200	□Paraplegia □Quadriplegia
□Variceal Bleeding	☐ Injection Drug Use, Current	☐Pregnant
☐ Hepatitis C	☐ Inflammatory Bowel Disease	☐Primary Immunodeficiency
Chronic Pulmonary Disease	☐Malignancy, Hematologic	Smoker, Current
Chronic Ulcer or Chronic Wound	☐Malignancy, Solid Organ (non-metastatic)	Transplant, Hematopoietic Stem Cell
☐Decubitus/Pressure Ulcer	Malignancy, Solid Organ (metastatic)	☐Transplant, Solid Organ
Surgical Wound	☐ Myocardial infarction	
Burn		
Other (specify):		

Last Updated: 11/15/2017

Page **2** of **5**

Version: Short Form 2017

State ID:	Date of Initial Culture (m	nm/dd/yyyy): _	//	Surveillar	nce Office Initials
OTHER CONDITIONS					
31. For cases ≤ 1 year of age: Ges				Birth weight:	gms 9 □Unknown
32. Infection with <i>Clostridium diffic</i> 1 □Yes 0 □No 9 □Unknown	·	<u>0 days after</u> ini	tial cultu	re date:	
32a. If yes, date of first <i>C. diff</i> diagnosis			nknown		
33. Surgeries in the <u>90 days before</u>				e <u>90 days before</u> initia	al culture date:
☐Abdominal surgery		1 □Yes			
□ Non-abdominal surgery (specify):		0			
□No surgery					
35. Was the patient neutropenic* 2	days before, the day before,	or on the day o	<u>f</u> initial c	ulture date?	
	n (no WBC days -2 or 0, or no diff	erential)			
35a. If yes, date of neutropenia (mm/da	<i>1/yyyy</i>):				
*Neutropenia: ANC ≤ 500	OR calculated as: WBC co	ount * (% poly	s + % ba	nds) ≤500	
36. Was the patient ever in an ICU i culture date?	n the 14 days before initial	37. Was the date?	patient e	ever in an ICU in the 1	4 days after initial culture
1 ☐Yes 0 ☐No 9 ☐Unknowr			0 □No	9 □Unknown	
38. Did the patient have a CVC 2 da		_	itial cult	ure date?	
	but can't find dates 9 Un	known			
38a. If yes, CVC type: (<i>Check all that ap</i> 1 □Nontunneled CVCs	<i>pply</i>) 3 □Implantable ports			6 □Other (specify): _	
2 Tunneled CVCs	4 □Peripherally inserte	d central cathete	r (PICC)	9 □Unknown	
38b. Were CVCs removed or changed in	the 7 days after initial culture da	te?			
1 □Yes		5 □Died or d	ischarged	before indwelling cathet	er replaced
2 □No		9 □Unknowr			
3 CVC removed, but can't find dates 39. Did the patient have a midline of	atheter 2 days before, the da	y before, or on	the day o	of initial culture date?	,
1 □Yes 0 □No 9 □Unknowr	·			_	
MEDICATIONS					
40. Did the patient receive systemic	antibacterial medication in t	he 14 days bef	ore initia	l culture date?	
1 ☐Yes 0 ☐No 9 ☐Unknown					
41. Did the patient receive total par	enteral nutrition (TPN) in the	14 days befor	e initial c	ulture date?	
1 Yes 0 No 9 Unknown					
42. Did the patient receive systemic if a different hospitalization)?	: antifungal medication during	g hospitalizatio	n, includ	ing the 14 days befor	e initial culture date (even
1 ☐Yes (if Yes, fill out question 45)	0 □No 9 □Unknown				
43. Was the patient prescribed syst		treat candide	mia, or w	as medication ongoin	g, at hospital discharge?
1 ☐Yes (if Yes, fill out question 46)	0 □No 9 □Unknown		•	_	<i>.</i>
44. If antifungal medication was no 1 □ Patient died before culture result av			-	vas the reason? icated culture result not	clinically significant
2 □Comfort care only measures were in				nented in medical record	, -
3 □ Patient discharged before culture re		6 □Unknowr		nened in medical record	
. addit district ged before culture re	Saic available to cillician	о Полиломі			
IF ANY ANTIFUNGAL ME	DICATION WAS GIVEN COM	DI FTF NEYT DA	GF OTHE	RWISE END OF CHAP	RT REVIEW FORM
IF ANT ANTIFORGAL ME	DICATION WAS GIVEN, COMP	PLLIL NEXT PA	GL. OIIIL	KWISL LIND OF CHAR	I KLAILAA LOKII

Version: Short Form 2017 Last Updated: 11/15/2017 Page **3** of **5**

Drug abbreviations (<u>NOTE:</u> Please use abbreviation when Amphotericin — any IV formulation (Amphotec, Amphocil, Fungizone, Abelcet, AmBiosome, etc.)=AMBIV Amphotericin — any inhaled formulation ()=AMBINH Anidulafungin (Eraxis)=ANF Caspofungin (Cancidas)=CAS			cil, Fluco Flucy Isuv Itrac	Fluconazole (Diflucan)=FLC Flucytosine (5FC)=5FC Isuvaconazole (cresemba)=ISU Itraconazole (Sporanox)=ITC Micafungin (Mycamine)=MFG		Other=OTH Posaconazole (Noxafil)=PSC UNKNOWN DRUG=UNK Voriconazole (Vfend)=VRC			
45. ANTII	FUNGAL MEDIC	ATION DURING HOSPIT	ALIZATION, INC	CLUDING THE 14	DAYS BEFORE INI	TIAL CULTURE DAT	TE (EVEN IF A DI	FFERENT	HOSPITALIZATION)
a. Drug Abbrev	n Firet da	nte given (<i>mm/dd/yyyy</i>)	c. Date start unknown	d. Last date giv	ven (<i>mm/dd/yyyy</i>)	e. Date stop unknown	f. Indicatio (Check if for propi		g. Reason for stopping ³
							Prophyla	xis	
							Prophyla	xis	
							Prophylaxis		
follow-up; (8)	3) not applicable, no ther	atment include: (1) completion of trapy given; and (9) unknown.	, , ,	3, , , ,	. 3, (,	•	omfort care only; (5) death	h; (6) other;	(7) no additional records/lost to
follow-up; (8) **If a medica	3) not applicable, no then action is given before init		inues taking that medica	ition after initial culture o	. 3, (,	•	omfort care only; (5) death	h; (6) other;	(7) no additional records/lost to
follow-up; (8) **If a medica	3) not applicable, no then action is given before init	rapy given; and (9) unknown. ial culture date and the patient cont	inues taking that medica	ISCHARGE	date, then put initial culture of	•	omfort care only; (5) deat 46 and as first date given	f. Tota	(7) no additional records/lost to
follow-up; (8) **If a medica	8) not applicable, no then attorn is given before init	rapy given; and (9) unknown. ial culture date and the patient cont ATION ONGOING OR PR	inues taking that medica	ISCHARGE c. Date start	date, then put initial culture of	date as last date given for Q	omfort care only; (5) deat 46 and as first date given	f. Tota	Il duration of post-
follow-up; (8) **If a medica	8) not applicable, no then attorn is given before init	rapy given; and (9) unknown. ial culture date and the patient cont ATION ONGOING OR PR	inues taking that medica	ISCHARGE c. Date start	date, then put initial culture of	date as last date given for Q	omfort care only; (5) deat 46 and as first date given	f. Tota	Il duration of post-
follow-up; (8) **If a medica	8) not applicable, no then attorn is given before init	rapy given; and (9) unknown. ial culture date and the patient cont ATION ONGOING OR PR	inues taking that medica	ISCHARGE c. Date start	date, then put initial culture of	date as last date given for Q	omfort care only; (5) deat 46 and as first date given	f. Tota	Il duration of post-

State ID: _____ Date of Initial Culture (mm/dd/yyyy): ___/___ Surveillance Office Initials _____

Version: Short Form 2017 Last Updated: 11/15/2017 Page **4** of **5**

State ID:	Date of Initial Culture (<i>mm/dd/yyyy</i>)://	Surveillance Office Initials
<u> </u>	bate of Initial Culture (IIIII) ad/yyyy)//	Surveillance Office Initials

AFST results for additional *Candida* isolates

Antifungal susceptibility testing (check here \square if no testing done/no test reports available):

Date of culture	Species	Drug	MIC		Interpreta	tion	
	1 □CA	Amphotericin B		□s	□SDD □I	□R	□NS
	2 □CG 3 □CK	Anidulafungin (Eraxis)		□s	□SDD □I	□R	□NS
		Caspofungin (Cancidas)		□s	□SDD □I	□R	□NS
	4 □CL	Fluconazole (Diflucan)		□s	□SDD □I	□R	□NS
	5 □CP 6 □CT	Flucytosine (5FC)		□s	□SDD □I	□R	□NS
	6 ∐CT 7 □CO	Itraconazole (Sporanox)		□s	□SDD □I	□R	□NS
	8 □CGN	Micafungin (Mycamine)		□s	□SDD □I	□R	□NS
	9	Posaconazole (Noxafil)		□s	□SDD □I	□R	□NS
	10 □Pending	Voriconazole (Vfend)		□s	□SDD □I	□R	□NS
	1	Amphotericin B		□s	□SDD □I	□R	□NS
		Anidulafungin (Eraxis)		□s	□SDD □I	□R	□NS
		Caspofungin (Cancidas)		□s	□SDD □I	□R	□NS
		Fluconazole (Diflucan)		□s	□SDD □I	□R	□NS
		Flucytosine (5FC)		□s	□SDD □I	□R	□NS
		Itraconazole (Sporanox)		□s	□SDD □I	□R	□NS
		Micafungin (Mycamine)		□s	□SDD □I	□R	□NS
		Posaconazole (Noxafil)		□s	□SDD □I	□R	□NS
	10 ☐Pending	Voriconazole (Vfend)		□s	□SDD □I	□R	□NS

Antifungal susceptibility testing (check here \square if no testing done/no test reports available):

Date of culture	Species	Drug	MIC	Interpretation			
	1	Amphotericin B		□s	□SDD □I	□R	□NS
	2 □CG 3 □CK	Anidulafungin (Eraxis)		□s	□SDD □I	□R	□NS
		Caspofungin (Cancidas)		□s	□SDD □I	□R	□NS
	4	Fluconazole (Diflucan)		□s	□SDD □I	□R	□NS
	5 □CP 6 □CT	Flucytosine (5FC)		□s	□SDD □I	□R	□NS
	7 □CO	Itraconazole (Sporanox)		□s	□SDD □I	□R	□NS
	8 □CGN	Micafungin (Mycamine)		□s	□SDD □I	□R	□NS
	9	Posaconazole (Noxafil)		□s	□SDD □I	□R	□NS
	10 ☐Pending	Voriconazole (Vfend)		□s	□SDD □I	□R	□NS
	1	Amphotericin B		□s	□SDD □I	□R	□NS
	2 □CG	Anidulafungin (Eraxis)		□s	□SDD □I	□R	□NS
	3 □CK 4 □CL 5 □CP 6 □CT 7 □CO 8 □CGN 9 □CS	Caspofungin (Cancidas)		□s	□SDD □I	□R	□NS
		Fluconazole (Diflucan)		□s	□SDD □I	□R	□NS
		Flucytosine (5FC)		□s	□SDD □I	□R	□NS
		Itraconazole (Sporanox)		□s	□SDD □I	□R	□NS
		Micafungin (Mycamine)		□s	□SDD □I	□R	□NS
		Posaconazole (Noxafil)		□s	□SDD □I	□R	□NS
	10 ☐Pending	Voriconazole (Vfend)		□s	□SDD □I	□R	□NS

Version: Short Form 2017 Last Updated: 11/15/2017 Page **5** of **5**